Approval · Notice of Compliance 27763 · 2022
XEOMIN: Notice of Compliance 27763
Issued March 15, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 27763
- Date
- March 15, 2022
- Company
- Merz Pharmaceuticals GmbhFrankfurt, Hessen, Germany
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Modification to the wording of the following indication: for the treatment of spasticity of the upper limb in adults
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| XEOMIN | Not yet assigned | — |
Medicinal ingredients
- INCOBOTULINUMTOXINA 50 UNIT per VIAL
- INCOBOTULINUMTOXINA 100 UNIT per VIAL